1
Miyake Kazutoshi, Matsukura Masayuki, Yoneda Naoki, Hiroshima Osamu, Mori Nobuyuki, Ishihara Hiroki, Musha Takashi, Matsuoka Toshiyuki, Hamano Sachiyuki, Minami Norio: Biphenylmethane derivative, the use of it and pharmacological compositions containing same.. Eisai, April 3, 1991: EP0420237-A1 (67 worldwide citation)

The biphenylmethane derivative having the formula (I) is disclosed in which R1 is hydrogen, an alkyl, a cycloalkyl, a halogenated alkyl, -S-R7, -SO2-R7, -C IDENTICAL C-R7 or -(CH2)p-OR7, R7 being hydrogen, an alkyl, a cycloalkyl or a halogenated alkyl, p being zero or 1, -A1=A2-A3=A4- is -CH=CH-CH=C ...


2
Watanabe Nobuhisa, Kabasawa Yasuhiro, Takase Yasutaka, Ozaki Fumihiro, Ishibashi Keiji, Miyazaki Kazuki, Matsukura Masayuki, Souda Shigeru, Miyake Kazutoshi, Ishihara Hiroki, Kodama Kohtaro, Adachi Hideyuki: Fused pyridazine compound. Eisai, July 24, 1996: EP0722936-A1 (29 worldwide citation)

A fused pyridazine compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof which exhibits an inhibitory activity against cyclic GMP phosphodiesterase (hereinafter referred to as "cGMP-PDE"). The compounds are useful as preventive and therapeutic agent ...


3
Takase Yasutaka, Watanabe Nobuhisa, Adachi Hideyuki, Kodama Kohtaro, Ishihara Hiroki, Saeki Takao, Souda Shigeru: Quinazoline compound.. Eisai, August 30, 1995: EP0669324-A1 (13 worldwide citation)

A quinazoline compound represented by general formula (I), which is useful as a medicine having the activity as a calmodulin-dependent cGMP-PDE inhibitor, or a pharmacologically acceptable salt thereof wherein R, R, R, R and R represent each independently hydrogen, lower alkyl, etc.; and R ad R repr ...


4
Ozaki Fumihiro, Ishibashi Keiji Parkhill Tsuku, Ikuta Hironori, Ishihara Hiroki, Souda Shigeru: Anthranilic acid derivative. Eisai, December 13, 1995: EP0686625-A1 (12 worldwide citation)

An anthranilic acid derivative having a cGMP-PDE inhibitory activity and represented by general formula (I), or a pharmacologically acceptable salt thereof wherein R, R, R and R represent each independently hydrogen, halogen, hydroxy, optionally halogenated lower alkyl, optionally halogenated lower ...


5
Yamanaka Motosuke, Hoshiko Tomonori, Suda Shinji, Yoneda Naoki, Mori Nobuyuki, Shino Mitsumasa, Ishihara Hiroki, Saito Mamoru, Matsuoka Toshiyuki: Pyrrolidine compound and pharmaceutical use.. Eisai, August 8, 1990: EP0381235-A2 (8 worldwide citation)

A pyrrolidine compound having the formula and a pharmacologically acceptable salt thereof is disclosed. It is useful in the pharmaceutical field. in which X is hydrogen, a halogen, or a lower alkyl, Y is -(CH2)n-, n being zero, 1 or 2, -S(O)p-, p being zero, 1 or 2, -O-, or -NH- and R is phenyl, a s ...


6
Suzuki Yuichi, Ito Koichi, Sasaki Atsushi, Ueno Koshi, Sakai Miyuki, Ishihara Hiroki, Kubota Atsuhiko: (Ja) ピペリジン環を有するインドール誘導体, (En) Indole derivatives having piperidine rings. Eisai R & D Management, Suzuki Yuichi, Ito Koichi, Sasaki Atsushi, Ueno Koshi, Sakai Miyuki, Ishihara Hiroki, Kubota Atsuhiko, ASAMURA Kiyoshi, November 17, 2005: WO/2005/108389 (8 worldwide citation)

(EN) Compounds represented by the general formula (I) or pharmacologically acceptable salts thereof; and use of the same as drugs: [wherein R1 and R2 are adjacent substituents and R1 and R2 together with the two carbon atoms to which they are bonded respectively form a 5- to 7-membered nonaromatic h ...


7
Matsunaga Manabu, Ishihara Hiroki, Sakai Zuisetsu, Ueno Tsugushi, Kitazawa Noritaka, Sasaki Atsushi, Takahashi Keiko, Kawano Koki, Okabe Tadashi, Suzuki Yuichi, Yamamoto Noboru, Komatsu Makoto: Therapeutic agent for uropathy. Eisai, April 16, 2002: JP2002-114684 (4 worldwide citation)

PROBLEM TO BE SOLVED: To obtain a new medicine excellent as a therapeutic agent and a prophylactic agent for uropathy diseases, especially urinary disturbance.SOLUTION: This medicine useful as the therapeutic agent and the prophylactic agent comprises a compound of formula (I) [A is a group represen ...


8
Ozaki Fumihiro, Kaneko Toshihiko, Tabata Mutsuko, Takahashi Yoshinori, Miyazaki Kazushiro, Kamata Junichi, Yoshida Ichiro, Matsukura Masayuki, Suzuki Hiroyuki, Yoshinaga Takashi, Ishihara Hiroki, Kato Koji, Sawada Kohei, Onoki Tatsuhiro, Kobayashi Kiyoaki, Okubo Miyuki: New piperidine compound and medicine containing the same. Eisai, October 2, 2001: JP2001-270883 (4 worldwide citation)

PROBLEM TO BE SOLVED: To obtain a new compound having excellent Na+ channel inhibiting activity. SOLUTION: This compound is represented by general formula (I) [wherein ring A is a ring, or the like, of general formula (II) (wherein R1 is hydrogen atom, or the like; and R2 is hydrogen atom, or the li ...


9
Kamada Masashi, Ohnishi Tadashi, Kato Manabu, Ishihara Hiroki, Fujiwara Tatsuo, Yamamoto Masaki: Fan guard of blower unit and air conditioner. Daikin, August 1, 2001: EP1120571-A1 (4 worldwide citation)

A frame (4a) is provided around the perimeter of the air outlet (2a) of the fan (6). The frame (4a) includes a plurality of board-shaped ribs (41, 41 ...) extending radially outward from the vicinity of the center of the frame (4a) in the direction of the radius of the fan (6). The frame (4a) also i ...


10
Watanabe Nobuhisa, Kabasawa Yasuhiro, Abe Shinya, Shibazaki Mayu, Ishihara Hiroki, Kodama Kohtarou, Adachi Hideyuki: Eisai, June 9, 1999: EP0920868-A1 (3 worldwide citation)

The present invnetion provides a remedy for erectile dysfunction. The active ingredient thereof is a fused pyridazine compound represented by the following formula (I) or a pharmacologically acceptable salt thereof: (wherein the ring C represents a 5 or 6 membered ring optionally having hetero atom( ...